- Home
- RVPHW vs GRABW Comparison
RVPHW vs GRABW Comparison
Compare RVPHW & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- GRABW
- Stock Information
- Founded
- RVPHW N/A
- GRABW N/A
- Country
- RVPHW United States
- GRABW Singapore
- Employees
- RVPHW 15
- GRABW 10604
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- GRABW Business Services
- Sector
- RVPHW Health Care
- GRABW Consumer Discretionary
- Exchange
- RVPHW Nasdaq
- GRABW Nasdaq
- Market Cap
- RVPHW N/A
- GRABW N/A
- IPO Year
- RVPHW 2018
- GRABW N/A
- Fundamental
- Price
- RVPHW $0.09
- GRABW $0.22
- Analyst Decision
- RVPHW
- GRABW
- Analyst Count
- RVPHW 0
- GRABW 0
- Target Price
- RVPHW N/A
- GRABW N/A
- AVG Volume (30 Days)
- RVPHW N/A
- GRABW N/A
- Earning Date
- RVPHW N/A
- GRABW N/A
- Dividend Yield
- RVPHW N/A
- GRABW N/A
- EPS Growth
- RVPHW N/A
- GRABW N/A
- EPS
- RVPHW N/A
- GRABW N/A
- Revenue
- RVPHW N/A
- GRABW N/A
- Revenue This Year
- RVPHW N/A
- GRABW N/A
- Revenue Next Year
- RVPHW N/A
- GRABW N/A
- P/E Ratio
- RVPHW N/A
- GRABW N/A
- Revenue Growth
- RVPHW N/A
- GRABW N/A
- 52 Week Low
- RVPHW N/A
- GRABW N/A
- 52 Week High
- RVPHW N/A
- GRABW N/A
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- GRABW 55.28
- Support Level
- RVPHW N/A
- GRABW $0.22
- Resistance Level
- RVPHW N/A
- GRABW $0.24
- Average True Range (ATR)
- RVPHW 0.00
- GRABW 0.02
- MACD
- RVPHW 0.00
- GRABW 0.00
- Stochastic Oscillator
- RVPHW 0.00
- GRABW 37.10
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About GRABW Grab Holdings Limited Warrant
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.